Background: Epstein-Barr virus (EBV) is a γ-herpesvirus that preferentially infects B cells and
establishes life-long chronic infection in more than 90% of the adult human population
worldwide. The virus-host balance is mainly sustained by T-cell responses, which are
able to control the infection asymptomatically. However, when T-cell immune control
fails, EBV is associated with a number of human malignancies such as Burkitt’s lymphoma,
Hodgkin’s lymphoma and nasopharyngeal carcinoma. Existing vaccine strategies against
EBV have not proven to be sufficient to combat EBV-associated tumors. Therefore, this
project aims to develop new EBV vaccine candidates to prevent and to treat EBV-associated
malignancies.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
P06.03
Identification
Copyright
© 2018 Published by Elsevier Inc.
